bluebird bio, Inc.

Home » bluebird bio, Inc.

Secondary

bluebird bio, Inc.

With its lentiviral-based gene therapies, T cell immunotherapy expertise and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and cancer.

Symbol

BLUE

Last Closing Price
$190.95

Shares
2,950,000

Effective Date
December 13, 2017

Underwriters
Goldman Sachs, BofA Merrill Lynch, J.P. Morgan, Cowen

To view the prospectus for bluebird bio, Inc., or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253